摘要
目的:观察舒血宁注射液对冠心病患者血液流变学和炎性因子的影响。方法:238例冠心病患者随机分为治疗组(129例)和对照组(109例),对照组采用常规西药治疗;治疗组在常规治疗基础上给予舒血宁注射液20ml,用5%葡萄糖注射液稀释成250ml,静脉滴注,1次/d。两组患者均治疗14d为1疗程。结果:①治疗组总有效率(86.0%)显著好于和对照组(64.2%),P<0.05;②治疗后治疗组全血黏度高切变率[ηbH(3.8±1.1)mPa/s∶(5.9±1.2)mPa/s]、全血黏度低切变率[ηbL(12.8±2.1)mPa/s∶(15.2±2.0)mPa/s]、血浆比黏度[ηp(2.2±0.2)mPa/s∶(3.0±0.4)mPa/s]、全血还原黏度[ηH(10.8±2.2)mPa/s∶(13.9±3.5)mPa/s]、血细胞比容[HCT(0.7±0.1)∶(0.8±0.1)]和纤维蛋白原[Fib(4.0±0.9)g/L∶(4.4±1.1)]g/L均较治疗前明显下降(P均<0.05),而对照组治疗前后比较除HCT、Fib外其它指标差异无显著性(P>0.05);治疗后两组比较,治疗组除HCT、Fib外其它指标明显优于对照组(P<0.05);③治疗后两组白细胞介素-6[治疗组(23.5±14.5)ng/L∶(59.3±12.1)ng/L,对照组(40.3±16.2)ng/L∶(61.6±14.7)ng/L]、肿瘤坏死因子α[治疗组(40.3±16.2)ng/L∶(254.4±55.6)ng/L,对照组(127.5±31.8)ng/L∶(257.0±44.9)ng/L]和高敏C反应蛋白[治疗组(4.1±0.9)mg/ml∶(6.1±1.2)mg/ml,对照组(5.0±1.0)mg/ml∶(6.0±1.1)mg/ml]均较治疗前明显下降(P均<0.05),治疗后两组比较,治疗组各指标均明显优于对照组(P均<0.05);④治疗后治疗组的一氧化氮[NO(48.2±7.2)mmol/L∶(43.4±8.5)mmol/L]、内皮素[ET(82.7±7.3)ng/L∶(89.2±12.5)ng/L]及NO/ET[(0.58±0.14)∶(0.49±0.11)]均较治疗前有非常明显的改善(P均<0.05),而对照组治疗前后差异则无显著性(P均>0.05)。结论:舒血宁注射液能明显降低冠心病患者的血液黏度,炎性因子水平,进而调节血管内皮活性,增加供血量,显著提高疗效。
Objective: To investigate the effects of Shuxuening injection on hemorheology and inflammatory factors in patients with coronary heart disease (CHD), Methods: A total of 238 eases with CHD were randomly divided into treatment group (n= 129) and control group (n= 109) . The control group was given routine therapy. The treatment group were given Shuxuening injection 20 ml (1 time/d, iv drop) based on routine therapy. The two group were trea- ted for 14d all. Results: (1)The total effective rate (86.0%) of treatment group was more than that of control group (64. 2%), P〈O. 05; (2)After treatment, η/bH [(3. 8±1.1) mPa/s vs. (5.9±1.2) mPa/s], ηbL [(12. 8±2. 1) roPa/s vs. (15.2±2.0) mPa/s], r/p [ (2.2±0.2) mPa/s vs. (3.0±0.4) mPa/s], r/H [ (10.8±2.2) mPa/s vs. (13.9± 3.5) mPa/s], HCT [ (0.7±0.1) vs. (0.8±0.1)], and Fib [Fib (4.0±0.9) g/L vs. (4.4±1.1) g/L] in treat- ment group were significantly decreased compared with before therapy (P〈0.05 all) , while there were no significant difference except for HCT and Fib in control group (P〉0.05). There were significant difference in above indexes ex- cept for HCT and Fib between the two groups after treatment (P〈0.05) ; (3)After treatment, IL--6 [treatment group (23.5±14.5) ng/L vs. (59.3±12.1) ng/L, control group (40. 3±6.2) ng/L vs. (61.6±14.7) ng/L], TNF-α [treatment group (40. 33±16.2) ng/L vs. (254.4±55.6) ng/L, control group (127.5±31.8) ng/L vs. (257. 0± 44. 9) ng/L], and hs--CRP [treatment group (4. 1:]=0. 9) mg/ml vs, (6.1±1.2) mg/ml, control group (5.0±1. 0) mg/ml vs. (6.0±1.1) mg/ml] in the two groups were significantly decreased (P〈0.05 all), but the treatment group had a better result compared with control group (P〈20.05) ; (4)After treatment, NO [(48.2±7.2) mmol/L vs. (43.4 ±8.5) mmol/L], ET[(82.7±7.3) ng/Lvs. (89.2±12.5) ng/L], and NO/ET [(0. 58±0.14) vs. (0.49±0.11)] were significantly improved in treatment group (P〈0. 05 all), but the control group no produced significant difference (P〉0. 05 all). Conclusion: Shuxuening injection can significantly reduce blood viscosity, inflammatory factors, im- prove blood vassel endothelial function and increase blood stream and therapeutiz effect.
出处
《心血管康复医学杂志》
CAS
2010年第5期552-555,共4页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
冠状动脉疾病
C反应蛋白质
血液粘度
Coronary artery disease
C reactive protein
Blood viscosity